Myristyl nicotinate

Drug Profile

Myristyl nicotinate

Alternative Names: Nia-114; Niacin prodrug - Niadyne Pharma; Tetradecyl nicotinate

Latest Information Update: 19 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Niadyne
  • Developer Niadyne; University of Arizona
  • Class Antineoplastics; Nicotinic-acids; Skin disorder therapies
  • Mechanism of Action GPR109A receptor agonists; GPR109B receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Skin cancer
  • Clinical Phase Unknown Plaque psoriasis

Most Recent Events

No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top